Innealta Capital LLC Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 196 shares of the biotechnology company’s stock, valued at approximately $31,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SRPT. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $28,000. Riggs Asset Managment Co. Inc. raised its stake in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the period. New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth approximately $32,000. Principal Securities Inc. purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at approximately $26,000. Finally, GAMMA Investing LLC grew its stake in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 87 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT stock opened at $135.78 on Friday. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The stock has a market cap of $12.83 billion, a price-to-earnings ratio of 1,234.36 and a beta of 0.89. The business has a fifty day moving average of $145.03 and a two-hundred day moving average of $132.94.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the firm earned ($0.27) EPS. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current year.

Analyst Ratings Changes

SRPT has been the topic of several research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, August 15th. Oppenheimer upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research note on Tuesday, May 14th. Piper Sandler decreased their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Citigroup dropped their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, Robert W. Baird raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $186.22.

Insider Buying and Selling

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the sale, the insider now directly owns 21,261 shares in the company, valued at approximately $3,467,243.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.